by Elec23 | Nov 5, 2024 | News&events
VisMederi is pleased to announce its inclusion in the distinguished 2023 list of the 300 fastest-growing companies, published by the Financial Times in partnership with Statista. VisMederi is proud to be ranked #188 among the leading organizations that have made great...
by Elec23 | Nov 4, 2024 | News&events
VisMederi Group is pleased to announce the publication of our latest collaborative research with GlaxoSmithKline’s Vaccine Global Health Institute (GVGH) in Frontiers in Immunology. This study addresses a critical challenge in global health: the prevention and control...
by Elec23 | Oct 18, 2024 | News&events
VisMederi is pleased to announce the publishing of a collaborative study with GVGH (GSK Vaccines Institute for Global Health) that highlights a significant achievement in vaccine research. This recent study, published in Frontiers in Immunology, describes the creation...
by Elec23 | Oct 8, 2024 | News&events
For those wishing to fully immerse themselves in the serological techniques required by regulatory agencies including the FDA, EMA, and PMD for the licensing and approval of viral vaccines, a 12-week program has been developed by Trialect and VisMederi Foundation....
by Elec23 | Sep 30, 2024 | News&events
European Night of Female Researchers and Scientists in Tuscany is known as Bright Night. Whether geographic, historical, artistic, literary, scientific, or psychological, the 2024 Bright Night’ s focus was travel. Bright Night pairs the word night with the...
by Elec23 | Sep 27, 2024 | News&events
VisMederi will be attending the World Vaccine Congress Europe 2024, taking place from October 28th to 31st at Fira de Barcelona, Montjuïc. The significance of this event brings together leading minds from the life sciences and public health fields to discuss the most...
